Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera - PubMed (original) (raw)
Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera
J Albert et al. AIDS. 1990 Feb.
Abstract
The kinetics of appearance and specificity of HIV-1 neutralizing antibodies was studied in four individuals. HIV-1 was isolated during symptomatic primary HIV-1 infection and repeatedly thereafter, and tested against autologous sera collected in parallel. Our patients developed isolate-specific low-titer neutralizing antibodies within 2-4 weeks, and the titers to the first isolates increased with time. We documented the emergence of virus variants with reduced sensitivity to neutralization by autologous, but not heterologous, sera in three patients. These virus variants were not, however, resistant to neutralization per se, since they were readily neutralized by the positive control serum. Our patients did not develop antibodies capable of neutralizing the new virus variants during the observation period. This suggests either a failure of the immune system to respond to the new virus variants or a mechanism by which the virus evades detection by the immune system. The emergence of neutralization-resistant virus variants was not directly correlated with disease progression since two patients have remained asymptomatic after the emergence of such virus variants. It is, however, likely that the emergence of virus variants which the patient fails to neutralize in the long run contributes to disease progression.
Similar articles
- Autologous HIV-1 neutralizing antibodies: emergence of neutralization-resistant escape virus and subsequent development of escape virus neutralizing antibodies.
Arendrup M, Nielsen C, Hansen JE, Pedersen C, Mathiesen L, Nielsen JO. Arendrup M, et al. J Acquir Immune Defic Syndr (1988). 1992;5(3):303-7. J Acquir Immune Defic Syndr (1988). 1992. PMID: 1740756 - Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals.
Moog C, Fleury HJ, Pellegrin I, Kirn A, Aubertin AM. Moog C, et al. J Virol. 1997 May;71(5):3734-41. doi: 10.1128/JVI.71.5.3734-3741.1997. J Virol. 1997. PMID: 9094648 Free PMC article. - Human immunodeficiency virus (HIV)-positive sera obtained shortly after seroconversion neutralize autologous HIV type 1 isolates on primary macrophages but not on lymphocytes.
Ruppach H, Nara P, Raudonat I, Elanjikal Z, Rübsamen-Waigmann H, Dietrich U. Ruppach H, et al. J Virol. 2000 Jun;74(12):5403-11. doi: 10.1128/jvi.74.12.5403-5411.2000. J Virol. 2000. PMID: 10823844 Free PMC article. - Isolate-specific neutralizing antibodies in patients with progressive HIV-1-related disease.
Von Gegerfelt A, Albert J, Morfeldt-Månson L, Broliden K, Fenyö EM. Von Gegerfelt A, et al. Virology. 1991 Nov;185(1):162-8. doi: 10.1016/0042-6822(91)90764-3. Virology. 1991. PMID: 1926772 - Neutralizing antibodies against sequential autologous human immunodeficiency virus type 1 isolates after seroconversion.
Tsang ML, Evans LA, McQueen P, Hurren L, Byrne C, Penny R, Tindall B, Cooper DA. Tsang ML, et al. J Infect Dis. 1994 Nov;170(5):1141-7. doi: 10.1093/infdis/170.5.1141. J Infect Dis. 1994. PMID: 7963706
Cited by
- Emergence of gp120 V3 variants confers neutralization resistance in an R5 simian-human immunodeficiency virus-infected macaque elite neutralizer that targets the N332 glycan of the human immunodeficiency virus type 1 envelope glycoprotein.
Sadjadpour R, Donau OK, Shingai M, Buckler-White A, Kao S, Strebel K, Nishimura Y, Martin MA. Sadjadpour R, et al. J Virol. 2013 Aug;87(15):8798-804. doi: 10.1128/JVI.00878-13. Epub 2013 May 29. J Virol. 2013. PMID: 23720719 Free PMC article. - HIV-1 neutralizing antibodies: understanding nature's pathways.
Mascola JR, Haynes BF. Mascola JR, et al. Immunol Rev. 2013 Jul;254(1):225-44. doi: 10.1111/imr.12075. Immunol Rev. 2013. PMID: 23772623 Free PMC article. Review. - Selection pressure on HIV-1 envelope by broadly neutralizing antibodies to the conserved CD4-binding site.
Wu X, Wang C, O'Dell S, Li Y, Keele BF, Yang Z, Imamichi H, Doria-Rose N, Hoxie JA, Connors M, Shaw GM, Wyatt RT, Mascola JR. Wu X, et al. J Virol. 2012 May;86(10):5844-56. doi: 10.1128/JVI.07139-11. Epub 2012 Mar 14. J Virol. 2012. PMID: 22419808 Free PMC article. - Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitro.
Barbas CF 3rd, Björling E, Chiodi F, Dunlop N, Cababa D, Jones TM, Zebedee SL, Persson MA, Nara PL, Norrby E, et al. Barbas CF 3rd, et al. Proc Natl Acad Sci U S A. 1992 Oct 1;89(19):9339-43. doi: 10.1073/pnas.89.19.9339. Proc Natl Acad Sci U S A. 1992. PMID: 1384050 Free PMC article. - A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralize several X4-, R5-, and dualtropic clade B and C primary isolates.
Verrier F, Burda S, Belshe R, Duliege AM, Excler JL, Klein M, Zolla-Pazner S. Verrier F, et al. J Virol. 2000 Nov;74(21):10025-33. doi: 10.1128/jvi.74.21.10025-10033.2000. J Virol. 2000. PMID: 11024131 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical